Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Revenue: 2016-2024

Historic Revenue for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $160.2 million.

  • Akebia Therapeutics' Revenue rose 57.01% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.1 million, marking a year-over-year increase of 1626.53%. This contributed to the annual value of $160.2 million for FY2024, which is 1501.80% up from last year.
  • Akebia Therapeutics' Revenue amounted to $160.2 million in FY2024, which was up 1,501.80% from $10.0 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Revenue high stood at $294.6 million for FY2020, and its period low was $10.0 million during FY2023.
  • Its 3-year average for Revenue is $154.2 million, with a median of $160.2 million in 2024.
  • In the last 5 years, Akebia Therapeutics' Revenue surged by 2,846.44% in 2020 and then slumped by 96.58% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Revenue (Yearly) stood at $294.6 million in 2020, then decreased by 28.17% to $211.7 million in 2021, then skyrocketed by 38.19% to $292.5 million in 2022, then tumbled by 96.58% to $10.0 million in 2023, then surged by 1,501.80% to $160.2 million in 2024.